Investor Relations

Media Archive

Media Archive

MediciNova in the News

MediciNova’s Drug Trial Addresses Methamphetamine Dependency – San Diego Business Journal – September 24, 2012 

Michael Coffee, Chief Business Officer, talks on eHealth Radio Network about a new asthma treatment to a new addiction treatment – September 7, 2012 

Dr. Yuichi Iwaki selected as one of the 100 of the Most Inspiring People in PharmaVoice July/August 2012 – IntroductionFull Article 

Interview with Michael Coffee, Chief Business Officer of MediciNova on The International Capitalist – June 6, 2012 

MediciNova Asthma Compound Poised for Late-Stage Trials – San Diego Business Journal – May 29, 2012

MediciNova to move into Phase 3 program – BioTuesdays – May 24, 2012

National Asthma Awareness Month: What’s Next in the Treatment of Acute Asthma? – Newswise – May 2012 

San Diego’s MediciNova Nears Turning Point with Lead Drug for Asthma – Xconomy – May 8, 2012

Click to read about Dr. Iwaki, President & CEO of MediciNova, featured in PharmaVoice – May 2012 

Click to watch a segment featuring MN-221 by NBC Philadelphia. 

Forward-Looking Statements

MediciNova cautions you that statements included in the company’s conference calls, press releases and other materials posted on, or available through, this website that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by MediciNova that any of its plans will be achieved. Actual results may differ materially from those discussed in the conference calls, press releases and other materials posted on, or available through, this website due to the risks and uncertainties inherent in MediciNova’s business including, without limitation: the progress and timing of its clinical trials; difficulties or delays in developing, testing, obtaining regulatory approval, manufacturing and commercializing its product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of its product candidates that could delay or prevent regulatory approval, product development or commercialization, or that could result in product liability claims; maintenance and enforcement of MediciNova’s licensing arrangements with its licensors; the scope and validity of patent protection for its product candidates; and other risks detailed in MediciNova’s Securities and Exchange Commission filings. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of such conference calls, press releases and other materials. All forward-looking statements are qualified in their entirety by this cautionary statement, and MediciNova undertakes no obligation to revise or update such statements to reflect events or circumstances after the date made. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.